Our investments in Alzheimer’s disease drug discovery research are getting tangible results. Specifically, ADDF supported research that:
- Screened millions of compounds, the chemicals that can become drugs
- Developed promising new chemicals and new classes of treatments
- Resulted in numerous patents filed and licenses for new drugs
- Advanced novel chemicals to human testing
- Invested more than $7 million in 33 biotechnology companies, which have received follow-on commitments of more than $1 billion
- Invested more than $35 million in new drug discovery programs worldwide